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Prevention of Maternal Rho (D) Sensitization

llist 2£YErythroblastosis fetalis is an ancient disease; the hydropic form
However, it was not until 1932 that

was probably known to Hippocrates.

three forms - hydrops, icterus gravis, and anemia of the newborn - were
shown to be the same disease. 26
the RH antigen in 1940.

Landsteiner and Wiener 47 discovered

The antigen was first found on the red cell of

the rhesus monkey, and hence its name, Rh factor.

In 1941, Levine 50

recognized the relationship between erythroblastosis fetalis and atypical
agglutinins in the mothers I serum which were identical to the anti-·Rh
agglutinin of Landsteiner.

Several of Levine's patients had transfusion

reactions after delivery when they received blood from their husbands.
He suggested that the infant inherited something from the father to which
the mother had antibody.

The antibody then crossed the placenta where

it caused the damage typical of erythroblastosis fetalis.

This theory

is the basis of Rh isoimmunization.
Levine

48 later added fetal-maternal ABO blood group incompatibility

to the causes of erythroblastosis fetalis and confirmed Landsteiner's
finding that Rh factor is inherited as a mendelian dominant gene.
The neonatal mortality of the disease was greatly reduced in 1947
when Diamond 23 proposed exchange transfusions.

Liley 51 introduced the

daring concept of intra-uterine transfusions as the next step in therapy
in 1964.
Two groups of investigators, working independently and using different approaches, found a method for preventing erythroblastosis

-2-

fetalis early in the 1960's.

Finn and Clark 29 in Liverpool, England

were impressed with Levine's finding that ABO incompatibility between the
mother and the fetus seemed to prevent isoimmunization of the mother
to the Rh factor. 49

This was believed to be because the ABO agglut-

inins cleared the fetal red cells from the mother's blood before Rh
isoimmunization could take place.

They reasoned, "It seemed that cir-

culating Rh positive fetal cells might be similarly eliminated by the
administration of anti-D (anti-Rho)' thus preventing sensitization of
the mother. n

'I'hey were able to prove this by injecting Rh positive

blood and serum from Rh sensitized women into Rh negative male volunteers.
At the same time, Freda, German, and Pollack 33 in the United States
were basing their work on the classical findings of Theobald Smith. 74
While working with Diphtheria toxin-antitoxin mixtures in 1909, Smith
showed that

!' •••

an excess of antitoxin reduces the possibility of

producing an active immunity, and may extinguish it altogether. ll

Freda's

group was able to prevent Rh-negative isoimmunization in male volunteers
with anti-Rh gamma-globin.

These results suggested an effective method

of preventing hemolytic disease of the newborn caused by Rh

o

isoim-

munization.
Research in the past decade has followed three principal directions.
Kleihauer 44 reported a simple and sensitive method for identifying fetal
red cells in adult blood in 1957.

Many workers have used this technique

to determine the frequency, timing and volume of transplacental fetalmaternal hemorrhage. 17,20,54,84

Other investigators have clarified

,-3the maternal immune response and attempted to find how it is suppressed
by passive gamma-globin. 46,72,77,80,87

The third approach has been

clinical trials with passively administered gamma-globin in Rho negative
mothers who have delivered Rho positive infants.

Several large series

have reported this treatment to be nearly one-hundred percent effective
in preventing Rh isoimmunization. 28,40,66
Diamond 24 recently commented on the unique history of hemolytic
disease of the newborn due to the Rh factor: llRarely has it been our
good fortune to have a disease recognized, its cause clearly determined,
its treatment successfully developed to a great extent, and then its
prevention found, all in one generation. 1i
Incidence
-----The Rho antigen (D) occurs in about

85%

of the Caucasian population.

It is present in only 70% of the Basques, 75% of the Negros, and is rarely
absent in Chinese, Japanese, and American Indians. 49

About 12% of fam-

ilies are at risk because of Rh incompatibility, but sensitization takes
place in only about 12% of these or 1.4% overall.

There are about

400,000 risk pregnancies per year in the U.S. and 20,000 to 40,000 new
sensitizations if no preventive treatment is used. 35

These estimates

agree with Smith 1 s series of 12,297 pregnancies in which 173 women or
1.4% became immunized to Rho. 73
Hemolytic disease of the newborn occurs in about 1.8% of all
deliveries.

This is caused by ABO incompatibility in 1.2%, Rho incom-

patibility in 0.6%, and rarely by other blood factors. 61

The perinatal

-4mortality in Rh affected infants has been reported as 36% when the
antibody appeared before the fifth month and 15% when it first appeared
after the sixth month. 52

The stillbirth rate in Rh hemolJ~ic disease

has remained about 15% resulting in about 5,000 stillbirths each year
in the United States. 26,30
TransElacental

hemorrha~~.

The first event in Rh hemolytic disease is the leakage of fetal
red cells into the maternal circulation.

This leakage is thought to

take place in the placenta, through breaks in fetal capillaries in
the chorionic villi.

The fetal cells then enter the intervillous

space and the mother's general circulation.

Research on transplacental

hemorrhage (TPH) has contributed heavily to the development of a method
of preventing maternal isoimmunization to the Rho antigen.
Most workers use the Kleihauer

44 technique to detect TPH.

is an acid elution method that destroyes adult red cells.

This

The preserved

fetal red cells then show up against a background of adult ghost cells.
Fetal hemorrhages as small as 0.1 mI. can be identified in the maternal blood by this technique. 88

This method is also used to

quanitate TPH; five cells per 50 low power microscope fields is equal
to 0.25 milliliters of fetal blood. 38

Although there is good agreement

with results from immunofluorescent methods, 19 the Kleihauer technique
has several possible errors that makes comparison of data from different laboratories difficult.

Fetal cells contain hemoglobin F

almost exclusively, but adult cells may also contain small amounts of
hemoglobin F. Which makes them show up with the Kleihauer technique.

-5Woodrow 84 found that hemoglobin F not due to fetal cells occurs in
6.3% of blood samples from pregnant women, in 2% of those from non-pregnant women, and 1.9% of those from a general hospital population.

One-

fourth of all slides have some irregularly stained cells and ndefinite
foetal cellsI' are occasionally seen in non-pregnant women.

Woodrow

suggests that three cells per 50 low power fields or 0.15 ml. be the
minimum criterium for TPH. 84
Other factors should be considered when studying TPH data.

Fetal

cells have a normal survival time ot about 80 days in the maternal circulation. 19,20,71)87

Thus, there is an additive effect from frequent

small hemorrhages as the pregnancy approaches term.

Hindemann 41 showed

that fetal red cells are absorbed from the adult peritoneal cavity and
sometimes do not appear in the circulation for as long as 13 days after
they are introduced.

He also found that late invasion of the maternal

blood by fetal red cells occurs in 3% of vaginal deliveries.

This pos-

sible transabdominal route could explain maternal sensitization when no
fetal cells were found immediately post-partum.
The frequency of TPH cannot be stated simply.

Many factors seem

to influence it, including how often fetal cells are searched for in
the maternal blood and how generous are the worker's criteria for TPH.
(See table 1).
are physiologic.

Cohen 19 believes that small transplacental hemorrhages
Clayton 17 found that fetal cells are present at some

time during pregnancy in 72% of pregnant patients when their blood is
examined at each pre-natal visit.
of TPH will be discussed below.

Other factors that alter the frequency

'rable 1
Transplacental Hemorrhage

--

Clinical Mater1al

Au thor

----

----

F nn 29

Fet.al cells
found
antepostpartum
Eartum

250 random deliveries

11.7%

Amount
considered
positive

any

Large
Hemorrhage

Comments

-

greater than
5 m1. in 1.5%

---"

z

pur sky 88

Wo odrow

-,

-

165 normal deliveries
132 with ABO compatible
infants
33 with ABO incompatible
infants

Co hen 19

any

15.8%

complicated obstetric
cases
,--

Br own 9

--

normal obstetric cases

Mc Larey 54

233 random pregnancies

54.3%

Wo odrow 84

700 random pregnancies
..... -

---_ .. _---

L ___

0.5ml.-4Oml. ir Kleihauer
and immuno10%
fluorescent
greater than
techniques
40ml. in 1%

50%

any

30%

any

greater than
3.0ml. in 3%

any

greater than
Kleihauer
O.5m1. in lO.3~ technique
one test per
patient

--"

-_

I»

Kleihauer
technique

40%

12%

-~---,----.-

I

53%

'-

_.. _"-----

-----V1

200 random pregnancies

.----------

Kleihauer
technique

any

50%

622 deliveries of ABO
compatible infants

83

greater than
0.5ml. in 0.5%
greater than
0.5m1. in 6.8%

19.8%
3.5%
all 3rd
trimester
~J_

---~--

..

_._ _---_._,,....

-.-

Kleihauer
technique

Kleihauer
technique

70.15 m1.
------_

I

--

-

~-~

....

- - - - - - - - -...- - . - - -

--

-----

)

Table 1 (con't)
A llthor

Clinical Material

._-_.-

Clayton

"

--,---

94 random and 100 Rh

17

-

s chneider

71

850 pregnancies
948 deliveries of ABO

Clarke

-

20

13

Large
Hemorrhage

any

greater than
Kleihauer
O.lml. in 10.8~ technique
tested each
prenatal visit
before onset
of labor

greater
than 0.05

15.6%
,

_.

(

6.2%

i~) ,.

0.8%

incompatible infants
Rh positive mothers with 52%
ABO incompatible infant
Rh negative mothers with 32%
Rh and ABO incompatible infants
All ABO compatible
mothers
1000 Rh negative women
458 with Rh positive
ABO compatible infants
348 with Rh negative ABO
compatible infants
119 with Rh positive
ABO incompatible infants
75 with Rh negative AB1
incomEatible infants

Comments

ml.

compatible infants

242 deliveries of ABO
Cohen

72%

Amount
considered
positive

negative pregnant
women

zipursky 87
"

Fetal cells
found
postanteIparj;um ipartum

1-.

greater
than O.1ml.
Vl

20%

any

5%

any

50%

any

18.6%

greater
than 0.25ml.
greater
than 0.25ml.
greater
than 0.25ml.
greater
than 0.25ml.

20.2%
4.2%
4.0%

0'

,,-

-6-

..

The time of the sensitizing dose of fetal cells is an important
and sometimes controversial point.

Fetal red cells are detected in

the maternal blood as early as the 14th week of gestation and in 12%
of pregnancies by the 20th week. 17
McLarey 54 found fetal cells in 54% of his patients between 21
and 42 weeks of gestation.

He found no increase in frequency during the

third trimester but showed that the volume of TPH increases as term
nears.

Woodrow 84 using stricter criteria, found evidence for TPH only

during the third trimester.

Woodrow 84 and Schneider 71 studying women

at term, demonstrated TPH in only 12% and 15.6% respectively.
Several studies have shown the incidence of fetal cells in manternal

-

blood postpartum to be about 50%. 9,19,20

Woodrow 84 found TPH greater

than 0.1, mI. in 19.8% of patients after delivery.

In a similar study

he reported fetal cells post-partum in 23% of patients who had no evidence
of TPH before delivery. 83

Clark 12 made retrograde injections of

tagged red cells through the umbilical vein at delivery.

He found sig-

nificant TPH in about one-third of his patients.
The volume of fetal-maternal hemorrhage varies from a trace to a
reported 250 ml. 53

Most evidence suggests that the larger hemorrhages

usually occur at term and during delivery.

McLarey 54 found that TPH

greater than 0.5 ml. occurred in 10% of pregnancies at some
delivery.

before

Clayton 17 found the same incidence for TPH greater than 0.1

ml. during pregnancy.

Hemorrhages larger than 0.25 ml. have been

reported in 9% and 16% of post-partum patients. ).3,83

-

~ime

Recently, massive

TPH has been described as the cause of newborn anemia and maternal trans-

-7fusion reactions. 5,19,53,63

These very large hemorrhages occur in

about 1% of pregnancies. 19,29
Fetal maternal ABO incompatibility has a significant effect on
TPH.

Both the incidence and volume of TPH are decreased in ABO incom-

patible pregnancies as compared to compatible pregnancies. 9.13,29,55,87,88
This difference may be due to rapid clearance of incompatible cells from
the maternal circulation; however, Cohen 20 showed normal survival of
ABO incompatible fetal cells in cases of massive TPH.
Cesarean section, large placentae, manual removal of the placenta.
and cervical laceration at delivery all are associated with increased
risk of 'I'PH. 9.55,58,88

Transabdominal amniocentesis does not seem to

increase TPH if done with ease. 10,85

Zipur sky

88

reported an increased

incidence in primiparas; however, other workers found no significant
relationship between TPH and maternal age, parity, previous abortion,
infarcted placentae, duration of labor, or Apgar of the infant. 9.54
Finally, fetal-maternal Rh incompatibility does not seem to protect
against TPH as effectively as ABO incompatibility. 13.54,87
These data suggest that transplacental hemorrhage, while common
during pregnancy, is rare before the third trimester.

Fetal cells are

present post-partum in about 50% of women and are present in volumes
greater than 0.25 ml. in about 10.% 81
Immunization
The Rh antigen is much more complicated than first thought.

There

are three pairs of allelomorphic genes and corresponding antigens in

_Wi

-8the Rh system.

These genes are inherited as mendelian dominants and

recessives which give rise to eight phenotJ~es. 26

(see Table 2).

In

addition, the Rho (D) antigen is made up of several components, some
of which may be absent in certain individuals.

These people, designated

DU , are Rh positive but make antibody to the complete D antigen. 6
Grobbelaar 37 believes that, "Many, possibly all, Rho antisera are polyvalent and contain a spectrum of antibodies of different specificities,
anti-Rho' anti-R0:1 etc.!'

The following discussion will be limited to

the Rho antigen which is the most antigenic and the only one which
commonly causes hemolytic disease of the newborn.

26,76

Smith 73 screened 12,297 random pregnancies and found that 1.4%
were immunized to Rho.

When only Rh negative women are studied, the rate

of immunization increases with the volume of fetal cells present after
delivery. (See Table 3).

Several workers agree that volumes of TPH

smaller than 0.1 ml. cause sensitization of from 2.6 to 4.6%>e:f' Rh negative women.

71,83,86 Zipursky 86 found that 15. 6%~ of Rh negative

mothers were immunized by TPH greater than 0.1 mI.

Finn 28 and Wood-

row 83 reported a 20% incidence with TPH greater than 0.25 mI.

The risk

of immunization may reach a limit of 50% as the volume of TPH rises above

5 to 10 ml. 82
Although the risk is less, more women may be immunized when no
fetal cells or only small volumes are demonstrated after delivery. 83,86
Delayed transabdominal passage of fetal cells into the maternal circulation
has been suggested as the cause of immunization when no TPH is found after
delivery. 41

,
,,~

~

,f

i

Table 2
Rho Isoimmunization
-~.,-.

Author

Material

ABO of infant

Number

Volume TPH

Immunized

Percent

Schneider 71

Rh negative
women

Any

39

greater than
0.05 ml.

1

Finn 28

Rh negative

Any

130

greater than
0.25 ml.

26

Woodrow 83

Rh negative
primiparas

Compatible

126
87
23

none
less than
0.25 ml.
0.25 ml. to
3.0 ml.
greater than
3.0 ml.

4
4

4.6
17

1

7.7

-

13
3
,

Pollack 66

Rh negative
women

Compatible

726

Rh negative

Compatible

84
54
30

not tested

2.5
20

2

67

51

7

2
6

3·7
20

!

'O:l
fO
I

..

Sullivan

._'0

78

..

Zipursky

86

Rh negative

Compatible

472
440
32

--

none
any

Less than
0.1 ml.
greater than
0.1 ml.

14

5

3
15.6

-

-9The time at which maternal sensitization occurs is critical and
somewhat controversial.

Most studies show that maternal antibodies to

the Rh factor develop within 6 months when none are found at delivery. 28,

43,66

u

~oo

d

row

83,84 feels that most slgnlflcant
. ..
TPH occurs at or just

before labor and that immunization begins at that time.

Since small TPH

occurs frequently during pregnancy 17,20.54 and more women are sensitized
by small volumes of fetal cells 83,86, Zipursky 87 believes that most
immunization occurs before labor.

Chown 11 found anti-Rho antibodies in

2% of Rh negative primagravidas at the time of delivery.

Using sensitive

tests, Krieger 46 found that twice as many Rh negative mothers were
immunized during pregnancy as during labor and delivery.

Many of these

would not be detected by direct Coombs tests on cord blood or by routine
post-partum serologic tests.

Bergstrom 3 found Rh antigen on the red

cells of a 38 day old fetus and suggests immunization by a previous early
abortion as the cause of antibodies in primagravidas.
immunizat~on

The higher risk of

during a second pregnancy suggests that some women with anti-

bodies are not identified. 66
As would be expected from its effect on TPH, ABO incompatibility
protects against Rh isoimmunization.

The incidence of ABO incompatible

matings in the general popUlation is 35%, while in those matings which
result in Rh hemolytic disease of the newborn the incidence is only 13
t o~.
25 tJ1

49,76 It has been shown .
.
ln Rh negatlve male volunteers that ABO

incompatible Rh positive blood is less capable of causing Rh isoimmunization.
Stern 77 showed that this protective effect is not due to maternal anti-A

-10-

or anti-B globulin blocking the Rh antigen sites on the fetal cells.
He felt that the theory of clonal competition for antibody best explained
this protection:

"The basic concept of this theory presupposes that

presence of clones of antibody-forming cells, each of which produces a
specific globulin which is identical with an antibody for a specific
antigen.

Exposure to the antigen results in proliferation of the corres-

ponding clone which then synthesizes large amounts of this globulin
and thus brings about appearance of circulating antibody.

The theory

explains differences between responses to primary and secondary exposure
to the antigen.!!

If, for instance, the Rh negative Type 0 mother has a

large clone producing anti-A globulin when exposed to fetal cells with
both A and Rho antigens . • , the anti-A clone will take up most of the
fetal cells.

This would allow little chance for the potential anti-

Rho close to be stimulated. 77
Hemolyzed cells are less antigenic than intact cells. 65,71
Pollack 65 believes that complement fixing antibody of the ABO system
hemolyzes fetal cells and they are cleared by the liver and kidney before
Rh immunization can occur.

Mollison 57 suggests that the ABO incompat-

ible fetal cells are taken up by the macrophages in the liver which is an
unfavorable site for antibody formation.
iihatever the mechanism, ABO incompatible fetal cells are not
found as often in the maternal circulation and are not as capable of
Rho isoimmunization as are compatible cells.

However, this protection

is not complete.
Other factors seem to influence the incidence of Rho immunization.

-

-11Taylor 79 found that the Rh type of the grandmother is significant in
Rh hemolytic disease.

An Rh negative women with an Rh positive mother

was more likely to have an affected infant by the third pregnancy than
a women with an Rh negative mother.

It is possible that these women

were sinsitized in-utero by their mothers.
As expected, there is an increased risk of immunization with complicated deliveries, probably a function of increased TPH. 59
There is also a variable individual response to Rho antigen in
all studies.

Not all women are immunized even with very large TPH.

Although the rate of immunization of volunteers increases with repeated
exposure and large amounts of antigen, 71 some Rh negative women do not
produce antibodies even after many Rh positive pregnancies.

Taylor 79

found that 88% of the women who produced antipodies, did so by three
Rh positive, ABO compatible pregnancies.

Woodrow 81 believes that preg-

nant women in general may be less susceptible to antigen stimulation.
The maternal immune system usually responds to the Rho antigen on
the surface of fetal red cells with antibody production.

Both macro-

phages and lymphoid tissue are involved in this response. 65
makes two types of antibody to the Rho antigen.

The mother

The first to appear is

a macroglobin, Igm, which has a molecular weight of 1,000,000, a sedimentation constant of 195, and is most active in a saline medium.

This

antibody is present in the serum for about one week then begins to
decrease as the second type of antibody increases. 69

This antibody,

IgG, has a molecular weight of 160,000, a sedimentation constant of 75,
and is most active in an albumin medium.

It has been suggested that IgG

-12is responsible for the end of IgM production.

72

The immune response

will be discussed in greater detail below.
The placenta is selective in allowing antibody to cross into the
fetal circulation.

The IgM macroglobins cannot cross while the IgG

antibodies are actively transported.

The transfer occurs directly

across the chorionic villi into the fetal circulation rather than
indirectly via the amnionic fluid.
the mother.

All fetal antibody is acquired from

The fetal gamma globin level remains low until

4 months of

pregnancy then rises to the maternal level at 9 months and may slightly
exceed it at term.

After birth, the infant begins to produce his own

antibody as the maternal antibody disappears.

The child's antibody

level does not reach adult levels again until about two years of age. 30
(See fig. 1).

In the fetal circulation the anti-Rho antibody destroys:::

fetal red cells and produces the changes characteristic of erythroblastosis fetalis.
The mother is only rarelt,-affected by Rho isoimmunization.

An

erythroblastotic maternal syndrome consisting of rapid fluid retention
without hypertension or proteinuria has been described in mothers with
severely affected fetuses.

All symptoms and signs disappear after

fetal death or delivery but increase in severity with the next pregnancy. 75
Rarely, large TPH causes transfusion reactions in Rh immunized mother. 63
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Prevention of Immunization
Since Levine described the cause of erythroblastosis fetalis,
interest has turned toward finding a way to prevent the disease.
Several workers have looked for ways to stop the leakage of fetal
cells across the placenta.

Doolittle 25 reduced the immunization rate

of Rh negative mothers with a delivery routine that stressed drainage
and spontaneous delivery of the placenta.

Messer 55 used an adren-

ergic drug that increases capillary resistence to injury and

.-.
-14lessens but does not eliminate 'I'PH.
The second approach is to limit the maternal immune response.
Hackel 39 found that components of nucleic acids lower the titer of
anti-Rh serum in vitro.
effect. 8,62

Sugars and amino sugars produce a similar

The amino sugars are part of the polysaccharide blood

group antigens and probably combine with antibody to lower titers. 62
The most successful method of preventing Rh hemolytic disease
is to suppress maternal antibody production with passive antibody
administration.

Finn 29 and Freda 33 are credited with the discovery

of this method.

In the first experiments Rh negative male volunteers

received both Rh positive blood and anti-Rh antibody.

The antibody

protected them from isoimmunization to the Rho antigen and produced no
side effects. 15,16,29,31,33,87

Clinical trials in postpartum Rh

negative women were then begun and a great deal of data is now available.

(See Table 3).

These stUdies show that anti-Rho gamma-globulin

is almost 100% effective in preventing the appearance of anti-Rho antibodies in the maternal serum after delivery of a Rh positive infant. 28,
40,66,67,71

In addition, some of these patients have been followed through

dence 0 f ~mmun~za
.
. t·~on. 28,40,66,
a secon d Rh pos~'t'~ve pregnancy w~'thout 'ev~
67,71
In addition, some few patients have been treated after more
than one Rh positive pregnancy with equally good results after as many
as four treatments.

40

A great deal more is known about the mechanism of immune response
and how it is prevented than was known at the time this treatment was

-15'
d
d lscovere.

F'lnn 29 assumed that the passive antibody would eliminate

the fetal cells before the mother was immunized.

Studies with Cr 51

tagged Rh negative red cells show that passive anti-Rh antibody does
increase the clearance of these cells. 29,87

The speed of clearance

is dose related; the rate of red cell destruction is proportional to
the square root of the amount of antibody on the cells. 57,71
figure 2)

(See

Delayed clearance of fetal cells is associated with maternal

immunization in cases of massive TPH protected with small doses of
passive antibody. 22,42

Clarke 15 suggested that 95% of the incom-

patible cells have to be removed within 24 hours to prevent immunization.
Most authors now believe that clearance of the fetal cells is
not as important as antigen competition in the prevention of maternal
immunization.

They base this belief upon what is presently known

about normal antibody production.
There are tW0 principal theories of the mechanism of antibody
production at the present time.

The clonal selection theory was

discussed above in connection with the protective effects of ABO
incompatibility, 77

This theory does not require the continued presence

of antigen for antibody production and has been largely supplanted
by the instructional theory.

According to this theory, antigen is

taken up by macrophages which have the capacity to induce antibody
formation in the lymphoid tissue.
RNA in response to antigen.

The macrophages produce messenger

The messenger RNA carries information

for IgM production to the lymphoid tissue.

'l'he macrophages are also

-16thought to release RNA-antigen complexes which seek out the already
committed lymphoid cells.

The antigen in the complex selects the

proper cells and gains entrance for the RNA.
IgG.

65

These cells then produce

This theory requires continued antigen stimulation for anti-

body production and still provides and explanation for the enhanced
response to a second dose of antigen.

The early appearance of IgM

in the immune response 69 tends to support this theory.

Figure 2
Relationship of Red Cell Clearance to Dose of Passive Antibody
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72 recently modified this theory to include the affinity of

circulating antibody as a control mechanism.

There is a marked dif-

ference in the affinity of antibody for antigen.
increases as the immune response continues.

This affinity

Siskind suggested that

antibody forming cells have antibody-like molecules on their surface
which captures antigen.
antibody.

They are then stimulated to produce more

Cells with the highest affinity molecules would have the

best chance to capture antigen and would produce antibody with high
affinity. 72

This would explain how circulating antibody prevents

.

.

hyperimmunization by feedback to the ant1body produc1ng cells.

27,72

These theories help explain some observations about the suppression of the immune response with passive antibody.

The passive anti-

Rho antibody is thought to combine with the Rho antigen and prevent it
from stimulating lymphoid cells to produce antibody.

72,80

The site of this interaction is

probably extra-circulatory.

27

no~

27,35,56,57,65,

known for certain but is

It is known that Rh antibodies cause

red cells to be sequestered and broken down in the spleen. 5r,65
Pollack 65 believes that passive antibody prevents macrophages from
processing antigen and producing messenger RNA.

The antibody may also

compete with lymphoid cells for RNA-antigen complexes necessary for
.
I gG pro duct10n.
.
65
cont1nued

Passively administered IgG antibody is more effective in supressing active immunization than IgM antibody.

27,72

Smaller doses of

high affinity antibody prevent immunization as well as larger doses

-18of low affinity antibody. 56,72

Since IgG is produced late in the

immune response it; would be expected to have a high affinity for
antigen and could successfully compete wit;h the lymphoid cells.
One disturbing result that was found in some trials was significant enhancement of immunization when passive antibody was
given.

15,18,22,65,72

This usually occurred when the doses of gamma

globin were relatively small.
· Rh negat 'l.ve men.
e ff ec t l.rl

Pollack 65 was able to demonstrate this

(S ee F'l.g. 3)

S·l.S k'l.na, 72 produced similar

results with very small doses of high affinity antibody.

He believes

that small doses of antibody cause suppression of only the low
affinity lymphoid cells, allowing the high affinity cells to produce
relatively more antibody than usual.
Figure 3
Enhancement of the Immune Response
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-19The amount of passive antibody necessary to suppress the maternal
immune response appears to depend upon the dose of antigen present.
The passive antibody is measured in micrograms of anti-Rho gammaglobin.

Equally good results are obtained with doses of 200 to 300

micrograms as with 1000 micrograms.

28 /6
,0

Most of the treatment

failures that have been reported are cases of very large fetal-maternal
22,42,82
hemorrhage.
Hughes-Jones 42 suggests that the absolute number of unbound antigen sites is the limiting factor in immune suppression.

There are about 12,000 Rho antigen sites on each fetal cell:

With TPH of 400 milliliters, 10,000 micrograms of gamma-globin would
be necessary to bind one-half of the antigen sites and suppress
immunization.

Seventy-five micrograms will occupy 10% of the sites on

one milliliter of fetal cells and prevent immunization.

The affinity

of the antibody for antigen as well as the dosage would affect the
numb er

0

f b oun d

"t es.

s~

42

There is some disagreement about when the passive antibody should
be administered.

Suppression is more difficult late in the immune

response but has been accomplished in animals as long as 40 days
80
72
after immunization.
Siskind
produced late suppression with
large doses of high affinity antibody.

Some authors believe that

immunization usually occurs during pregnancy rather than after delivery.

11,46,87

Z"

~purs

k

Y

87

found that anti-Rho gamma-globin given during

pregnancy is effective in preventing immunization and does no harm to
the fetus.

The half-life of human gamma-globin is about 30 days and

would provide prolonged protection if given during pregnancy. 35,87

-20-

In most large series the antibody is given within 72 hours of delivery
with excellent results.

28,66

Another important question is which patients should be protected?
Certa.inly, all Rh negative mothers with Rh positive ABO compatible
infants should receive gamma-globulin if they are not already immunized.
'rhe presence of fetal cells in the maternal circulation after delivery
should not be a requirement for protection. 66,78

Although ABO incom-

patibility is protective it is not completely effective.

49,76

These

patients with ABO incompatible infants probably should also receive
anti-Rho antibody.

66

In addition, treatment has been recommended

after early abortions and any manipulation likely to cause transplacental hemorrhage. 3,64
,I

~

There is very little risk to this treatment.
ser~~

The danger of

hepatitis has been eliminated by use of gamma-globulin prep-

arations.

Clarke

14

found that there is about a

ernal sensitization to gamma-globulin.

6%

incidence of mat-

This also occurs with blood

transfusions and rarely causes symptoms. 14

A few local skin reactions

at the site of injection and fevers lasting 24 hours have also been
reported.

13

There seems to be no damage to the immune system in gen-

.
.. f
.
. those treate d • 14
era1 and there .
~s no ~ncrease ~n 1n ect10ns ~n

Passive Rh antibody treatment may select against Rh-positive
fetuses in subsequent pregnancies.

Finn 28 found that 50% of the

treated Rh-negative women had Rh-positive infants with the next pregnancy.

This is a significant difference from the expected 80% incidence.

-

-21It is not yet clear whether this represents true selection or,
if so, what are its implications.
Discussion
There can be little doubt that anti-Rho gamma-globulin is a safe
and effective method of suppressing maternal Rho immunization.

The

treatment is still expensive; the price of one standard dose of antiRho gamma-globulin is $50.00 at the University of Nebraska Hospital.
However, the cost has been lowered and is expected to decrease further.
rfhe development of this treatment has contributed a great deal
to the basic understanding of the immune system.

The human Rho factor

is an important research tool because the antigen is normally absent
in a significant number of people, is naturally introduced into pregnant
women, and is easily identified with the Kleihauer technique.

It is

understandable that this is the first disease of an immune nature
for which a specific method of prevention has been developed.
Several questions about this method still need to be resolved.
There is some evidence that maternal isoimmunization usually begins
during pregnancy.

However, passive antibody given after delivery still

effectively suppresses maternal antibody production.

Animal studies

have shown that the immune response can be suppressed as long as 40
days after antigen is introduced.

It is possible, then, that some of

the treated mothers who have no antibody six months after delivery
actually were immunized during pregnancy and then suppressed by passive
gamma-globulin at delivery.

There is a marked difference in the sen-

sitivity of the serologic tests used in the clinical series and small

-

-22amounts of maternal anti-Rho antibody may be overlooked.

If this is

true, these women would be capable of an amnestic immune response
during a subsequent Rho positive pregnancy.

This problem will be

resoxved when more women have been followed through several Rho positive pregnancies.

It may be necessary to give gamma-globulin during

pregnancy as Zipursky suggests.
Another interesting question is raised by this line of thought.
Theoretically, the maternal immune response could be suppressed by
very large doses of IgM passive antibody.

This antibody does not

cross the placenta and could do no damage to the fetus.

Perhaps

erythroblastosis fetalis could be prevented even when the mother is
already immunized by giving

I~~

early in pregnancy.

There are other possibilities.

If antibody could be altered

so that it would still compete with the lymphoid cells for antigen
but could not produce the changes seen in auto-immune diseases, passive
antibody could be used to treat these disorders.

Perhaps small doses

of wlaltered, very high affinity antibody could accomplish this.
Whatever the future applications of these principles, it
seems likely that hemolytic disease of the newborn caused by the
Rho antigen will soon go the way of smallpox, diphtheria, and polio.
pummar,;y:
In the past 30 years Rho hemolytic disease of the newborn has
been recognized, its cause found, and its prevention developed.

This

disease occurs in about 0.6% of all deliveries and has a stillbirth
rate of about 15%, resulting in 5,000 stillbirths each year in the

____________________________
a _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

-23United States.
The leakage of fetal red cells across the placenta into the
maternal circulation is the first event in Rho hemolytic disease,
Many factors influence this transplacental hemorrhage; but in general,
TPH is very common during pregnancy, occurs during delivery in about
one-half of all patients, and is greater than 0.25 mI. in about 10%.
The mother then produces antibodies to the Rho antigen on the
fetal red cells.

The rate at which maternal isoimmunization occurs

depends on the dose of fetal cells, the ABO types of the mother and
fetus, and the variable individual response of the mother.

It is not

clear whether immunization usually occurs during pregnancy or after
delivery.
In affected pregnancies the anti-Rho IgG antibodies eross the
placenta and destroy fetal red cells.

There have been attempts to

interrupt this process at several points.

The most successful method

is suppression of the maternal immune response with passively administered anti-Rho gamma-globulin.

According to the instructional

theory of antibody production, the passive antibody competes with the
lymphoid cells and macrophages for antigen.

As expected, high affinity

antibody is more effective than low-affinity antibody and the antigenantibody ratio is critical in immune suppression.

The phenomenon of

enhancement of the immune response with small doses of passive gammaglobulin can also be explained with the present theories.
Passive anti-Rho gamma-globulin is a safe and very effective method
of preventing Rh-hemolytic disease of the newborn.

There is still some

-24question about the optimal time of administration and whether the
treatment is still effective after several Rh-positive pregnancies.
Continued clinical trials will soon answer both questions.

The prin-

ciples discovered during the development of this treatment may be
applicable to other immune diseases.
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